With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

TERT gene fusions characterize a subset of metastatic Leydig cell tumors

Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas

Comparative molecular analyses between BRAFV600E colorectal cancers and BRAFV600E melanomas

Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC)

Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix

WRN mutated Colorectal Cancer is characterized by a distinct molecular and immunological profile

Large-scale Analysis of CDH1 mutations defines a distinctive molecular subset in gastric cancer

Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridiza&on (FISH) and mutational analysis.

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities